Tariq Enezate

Tariq Enezate

Auto-generated profile, based on publicly available information

Tariq Enezate

Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, Missouri

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
TETariq H. Enezate
Tariq H. Enezate
JOJad Omran
Jad Omran
EMEhtisham Mahmud
Ehtisham Mahmud
MPMitul Patel
Mitul Patel
MAMazen S. Abu-Fadel
Mazen S. Abu-Fadel
AAAshraf S. Al-Dadah
Ashraf S. Al-Dadah
Background: A number of small studies have suggested that outcomes following endovascular (ENDO) therapy are comparable to those following surgical (SURG) revascularization for patients presenting with acute limb ischemia (ALI). We sought to compare mortality, limb amputation and recurrent ischemia across both revascularization strategies. Methods: A comprehensive database search of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) electronic databases from January 1990 through January 2016 was performed to identify studies of ENDO versus SURG for ALI. Two independent reviewers selected studies and extracted the data. Random-effects meta-analysis was used to pool results across studies. Heterogeneity of treatment effect among trials was assessed using the I2 statistics. The primary endpoints were mortality and limb amputation at 1 month, 6 and 12 months. Secondary endpoint was recurrent ischemia at one year. Results: A total of 1,773 patients were included from six studies (five randomized prospective and one observational retrospective) comparing ENDO and SURG in the setting of ALI. The mean age was 67 years and 65% of patients were male. There were no differences in mortality between the two groups at 1 month [risk ratio (RR) for ENDO vs. SURG is 0.70; 95% confidence interval (CI), 0.33 to 1.50], 6 months (RR 1.12; CI, 0.78 to 1.61) or 12 months (RR 0.74; CI, 0.29 to 1.85). Similarly, there was no significant difference in amputation rates between ENDO and SURG at 1 month (RR 0.75; CI, 0.40 to 1.42), 6 months (RR 0.87; CI, 0.52 to 1.48) or 12 months (RR 0.81; CI, 0.55 to 1.18). When looking into secondary outcomes, recurrent ischemia was not different between the two groups (RR 1.12; CI, 0.75 to 1.67). Conclusions: In patients presenting with ALI (<2 weeks of duration), ENDO and SURG approaches have similar rates of short-term and 12 month mortality, limb amputation and recurrent ischemia.

1 November 2017 in The American Journal of Cardiology
Verified
Journal Article
Closed access
TETariq H. Enezate
Tariq H. Enezate
JOJad Omran
Jad Omran
AAAshraf S. Al-Dadah
Ashraf S. Al-Dadah
MAMartin Alpert
Martin Alpert
EMEhtisham Mahmud
Ehtisham Mahmud
DBDeepak L Bhatt
Deepak L Bhatt

19 March 2019 in Heart Asia
Verified
Journal Article
Open access
PDF file
RGRugheed Ghadban
Rugheed Ghadban
TETariq Enezate
Tariq Enezate
JPJoshua Payne
Joshua Payne
HAHaytham Allaham
Haytham Allaham
AHAhmad Halawa
Ahmad Halawa
KAKul Aggarwal
Kul Aggarwal
Background Morphine is widely used for pain control in patients with acute coronary syndrome (ACS). Several studies have questioned the safety of morphine in this setting with a concern of interaction with and reduced efficacy of antiplatelet agents. Objective This study aims to systematically review the safety of morphine use in ACS. Methods MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were queried from inception through April 2018. Studies comparing morphine to nonmorphine use in ACS were included. Study endpoints included: in-hospital myocardial infarction (MI), all-cause mortality, stroke, major bleeding, minor bleeding and dyspnoea. Results A total of 64 323 patients with ACS were included from eight studies, seven of which were observational studies and one was a randomised controlled trial. The use of morphine was associated with increased risk of in-hospital recurrent MI (OR 1.30, 95% CI 1.18 to 1.43, p < 0.00001). There was, however, no significant difference in terms of all-cause mortality (OR 0.87, 95% CI 0.62 to 1.22, p = 0.44), stroke (OR 0.81, 95% CI 0.39 to 1.66, p = 0.57), major bleeding (OR 0.49, 95% CI 0.24 to 1.00, p = 0.05), minor bleeding (OR 0.98, 95% CI 0.41 to 2.34, p = 0.97), or dyspnoea (OR 0.55, 95% CI 0.16 to 1.83, p = 0.33). Conclusion The use of morphine for pain control in ACS was associated with an increased risk of in-hospital recurrent MI. Randomised clinical trials are needed to further investigate the safety of morphine in ACS.

5 October 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
TETariq Enezate
Tariq Enezate
JOJad Omran
Jad Omran
AAAshraf S. Al‐Dadah
Ashraf S. Al‐Dadah
MAMartin Alpert
Martin Alpert
CWChristopher J. White
Christopher J. White
EMEhtisham Mahmud
Ehtisham Mahmud

1 June 2018 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
OAObai Abdullah
Obai Abdullah
JOJad Omran
Jad Omran
TETariq Enezate
Tariq Enezate
EMEhtisham Mahmud
Ehtisham Mahmud
NSNicolas Shammas
Nicolas Shammas
AAAshraf Al-Dadah
Ashraf Al-Dadah

20 November 2017 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
TETariq H. Enezate
Tariq H. Enezate
JOJad Omran
Jad Omran
AAAshraf S. Al‐Dadah
Ashraf S. Al‐Dadah
CWChristopher White
Christopher White
MPMitul Patel
Mitul Patel
DBDeepak L. Bhatt
Deepak L. Bhatt